Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The National Cancer Institute’s Technology Transfer Center (TTC) facilitates partnerships between NIH research laboratories and external partners—companies, academia, non-profits, and other government agencies. The TTC is the guardian of NCI’s intellectual property from the point of discovery to invention development, patenting, and licensing.
BrightPath, formerly known as GreenPeptide, is moving beyond peptides to push the boundaries of cancer immunotherapy toward more personalized treatments.
Clinical-stage biopharmaceutical company Fate Therapeutics is creating first-in-class (re)programmed cellular immunotherapies for cancer and immune disorders. Preclinical and clinical development of the company’s product pipeline is driven by a determined pursuit of a new cell therapy paradigm and an expanding array of strategic partnerships to support its innovative mission
Through an innovative approach to both science and business, Ovid Therapeutics is developing impactful medicines for people with rare neurological disorders.
Brainstorm Cell Therapeutics is looking for financial and corporate partners to help complete the development and launch of revolutionary neurodegenerative disease treatments.
With several products in advanced clinical stages, such as oral CGRP-receptor antagonists and glutamate modulators, Biohaven is welcoming collaborations on these programs and broadening its pipeline further.
Abide Therapeutics’ lead product ABX-1431, which is about to reach phase 2 trials, is the first drug candidate to emerge from Abide’s unique platform for generating first-in-class serine-hydrolase-targeted therapeutics.
ABL Bio’s first-in-class bispecific antibodies for Parkinson’s disease combine unprecedented blood–brain barrier penetration with a robust mechanism of action for improved therapeutic efficacy. The company is looking for partners to codevelop or out-license bispecific antibodies able to penetrate the blood–brain barrier.
BioAxone is developing a suite of game-changing treatments for spinal cord injury, neurovascular diseases, and eye disorders by targeting Rho/Rho kinase signaling pathways involved in a variety of pathological processes.
Attracting both investors and big pharma, Mission Therapeutics is targeting a range of unmet medical needs, including Parkinson’s disease, with its unique deubiquitylating enzyme (DUB) platform.
The first ondansetron orally dissolving film (ODF) has been approved in Japan, validating TAHO’s platform technology from prototype to commercial product.
Probiodrug is using a multi-pronged approach to reduce brain levels of pyroglutamate–amyloid-β peptides; results from the SAPHIR IIa trial for the company’s lead candidate PQ912 reveal positive early efficacy data that are highly attractive for further development.
Indivior is investing in research and development to pioneer life-transforming treatments in addiction medicine, and in partnerships worldwide to realize its vision that all patients will have access to quality treatment for the chronic relapsing conditions and co-occurring disorders of addiction.
By using a tissue-specific hormone inhibitor to rebalance local estrogen metabolism, Forendo Pharma could provide long-term treatment to millions of women suffering from endometriosis.
Building on its history of successful collaborations, Sanofi Pasteur, the vaccines Global Business Unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.
C-Bridge Capital specializes in the growing Chinese health care market and is using its expertize to identify emerging industry leaders and bring global innovation into China.
